Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of Daridorexant in Chinese Healthy Subjects
NCT06326723Phase 1Completed
- Sponsor
- Simcere Pharmaceutical Group
- Start
- Sep 2023
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of daridorexant in Insomnia (2 arms), sponsored by Simcere Pharmaceutical Group. Primary endpoint: Pharmacokinetic Endpoints. Started Sep 2023; status: completed.
02
Drugs
daridorexant
03
Conditions
Insomnia
Beyond the preview
Go deeper on NCT06326723.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06326723.